Trajenta’s German Renaissance Nipped In The Bud; Revised Dossier Falls Short
This article was originally published in The Pink Sheet Daily
Executive Summary
Comparator issues have wrecked reimbursement prospects for the second time for Boehringer/Lilly’s diabetes drug Trajenta in Germany as authorities dispute the utility of a study published in The Lancet comparing the product to the sulphonylurea glimepiride.